Skip to main content
Livermore
Livermore
ZHEN

Corvus Pharmaceuticals, Inc.

CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001626971

No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Corvus Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Corvus Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Corvus Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Clark Ian TDirector–Jun 15, 20261
Thompson Peter A.Director, 10% Owner210,000Jun 15, 20262
Grais LindaDirector10,000Jun 15, 20261
van den Broek RichardDirector–Jun 15, 20261
Moore David ScottDirector21,700Jun 15, 20262
Miller Richard A MDPresident and CEO1,195,035IndirectMay 20, 20262
Chan Andrew C.Director–Apr 27, 20261
Lea LeivChief Financial Officer133,238IndirectDec 8, 20251
Jones William BentonSee Remarks173,130Dec 8, 20251
Arcara JeffreyChief Business Officer–Dec 8, 20251
OrbiMed Advisors LLCDirector, 10% Owner7,165,006IndirectJul 1, 20250
OrbiMed Capital GP V LLCDirector, 10% Owner7,165,006IndirectJul 1, 20250
Morrison Scott WDirector–Jun 16, 20250
Gould Terry PDirector, 10% Owner–Jun 17, 20240
Mitchell Edith P.Director–Dec 8, 20230
Adams Street Partners LLC10% Owner–Aug 15, 20220
EcoR1 Capital, LLC10% Owner81,077IndirectOct 1, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 23, 2021 (view filing)Aug 203 daysMiller Richard A MDPresident and CEOPPurchase+10.0K$1.93+$19.3K+0.8%1.29M after
Sep 22, 2021 (view filing)Sep 202 daysThompson Peter A.Director, 10% OwnerSSaleCommon Stock, $0.0001 par value−1.11M$6.09−$6.76M−13.8%6.94M after
Sep 22, 2021 (view filing)5:27 PM ETSep 202 daysOrbiMed Advisors LLC and 1 otherDirector, 10% OwnerSSaleCommon Stock, $0.0001 par value−1.11M$6.09−$6.76M−13.8%6.94M afterDuplicate filing
Oct 1, 2021 (view filing)Sep 30-Oct 11 dayEcoR1 Capital, LLC10% OwnerSSale−5.00M$5.01−$25.0M−98.4%81.1K after2 lots
Mar 17, 2022 (view filing)Mar 15-172 daysMiller Richard A MDPresident and CEOPPurchase+30.0K$1.49+$44.7K+2.3%1.32M after2 lots
Mar 17, 2022 (view filing)Mar 16-171 dayLea LeivChief Financial OfficerPPurchase+49.0K$1.57+$77.0K+97.7%99.2K after2 lots
Apr 1, 2022 (view filing)Mar 311 dayMiller Richard A MDPresident and CEOPPurchase+15.0K$1.64+$24.6K+1.1%1.33M after
Jun 6, 2022 (view filing)Jun 2-64 daysMiller Richard A MDPresident and CEOPPurchase+5.89K$0.9842+$5.80K+0.4%1.34M after3 lots
Jun 28, 2022 (view filing)Jun 24-274 daysMiller Richard A MDPresident and CEOPPurchase+10.0K$1.02+$10.2K+0.7%1.35M after2 lots
Sep 20, 2022 (view filing)Sep 20Same dayMiller Richard A MDPresident and CEOPPurchase+20.0K$0.8139+$16.3K+1.5%1.37M after3 lots
Sep 28, 2022 (view filing)Sep 28Same dayMiller Richard A MDPresident and CEOPPurchase+25.0K$0.76+$19.0K+1.8%1.39M after
Dec 15, 2022 (view filing)Dec 13-142 daysMiller Richard A MDPresident and CEOPPurchase+60.0K$0.7467+$44.8K+4.2%1.49M after2 lots
Dec 15, 2022 (view filing)Dec 13-142 daysLea LeivChief Financial OfficerPPurchase+34.0K$0.7518+$25.6K+34.3%133.2K after2 lots
Dec 20, 2022 (view filing)Dec 20Same dayJones William BentonSee RemarksPPurchase+20.0K$0.79+$15.8K+17.6%133.8K after
May 16, 2023 (view filing)May 151 dayGrais LindaDirectorPPurchase+10.0K$2.45+$24.5KNew position10.0K after
May 7, 2024 (view filing)May 61 dayMiller Richard A MDPresident and CEOPPurchase+577.6K$1.73+$999.3KNew position577.6K after
May 7, 2024 (view filing)May 61 dayMiller Richard A MDPresident and CEOPPurchase+559.1K–––559.1K afterDerivative
May 7, 2024 (view filing)May 61 dayJones William BentonSee RemarksPPurchase+20.0K$1.73+$34.6K+15.0%153.8K after
May 7, 2024 (view filing)May 61 dayJones William BentonSee RemarksPPurchase+19.4K–––19.4K afterDerivative
May 8, 2024 (view filing)May 62 daysThompson Peter A.Director, 10% OwnerPPurchase+2.84M$1.73+$2.50M–1.40M afterDerivative2 lots
May 8, 2024 (view filing)8:28 PM ETMay 62 daysOrbiMed Advisors LLC and 1 otherDirector, 10% OwnerPPurchase+2.84M$1.73+$2.50M–1.40M afterDerivative2 lots
Jul 1, 2025 (view filing)Jun 274 daysThompson Peter A.Director, 10% OwnerSSale−1.18M$4.16−$4.89M−14.1%7.17M after
Jul 1, 2025 (view filing)9:23 PM ETJun 274 daysOrbiMed Advisors LLC and 1 otherDirector, 10% OwnerSSale−1.18M$4.16−$4.89M−14.1%7.17M after
May 20, 2026 (view filing)May 182 daysMiller Richard A MDPresident and CEOPPurchase+6.93K$12.04+$83.5K+0.6%1.20M after2 lots
Jun 15, 2026 (view filing)Jun 114 daysMoore David ScottDirectorPPurchase+21.7K$11.53+$250.2KNew position21.7K after